Cytokinetics Releases Inaugural Corporate Responsibility Report

Cytokinetics Releases Inaugural Company Accountability Report

Cytokinetics, Included

Report Highlights Firm Dedication to Affected person Centricity, Sustainability, Ethics, Range, Fairness and Inclusion

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Included (Nasdaq: CYTK) at the moment introduced the discharge of its inaugural Company Accountability Report, outlining the Firm’s dedication to social and environmental duty, ethics and governance and affected person and group engagement.

“At Cytokinetics, being a accountable company citizen is a pure extension of our firm values, and to ensure that us to achieve success, our objectives should be aligned to the well-being of our workers and the communities that we serve and through which we function,” mentioned Robert I. Blum, Cytokinetics’ President and Chief Government Officer. “Company duty has all the time been a basic core precept that we apply to our work in advancing potential therapies for these residing with illnesses of impaired muscle operate; our inaugural report highlights our commitments and actions and formalizes our pledge to assist guarantee our plans and progress proceed in accordance with our guiding values.”

Cytokinetics’ inaugural report focuses on Empowering Lives within the communities it serves and highlights three strategic pillars as a framework for reporting. These pillars are:

  • Conserving sufferers on the heart of our work

  • Advancing a high-integrity, various and inclusive tradition

  • Supporting sustainable communities

The discharge of Cytokinetics’ inaugural Company Accountability Report is a part of its ongoing dedication to offering transparency and accountability on issues associated to company duty. The Firm intends to launch an annual replace to report on progress towards its objectives and to make sure that all stakeholders are stored knowledgeable. For extra info, please go to: www.cytokinetics.com/duty.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical firm targeted on discovering, growing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential therapies for debilitating illnesses through which muscle efficiency is compromised. As a pacesetter in muscle biology and the mechanics of muscle efficiency, the corporate is growing small molecule drug candidates particularly engineered to impression muscle operate and contractility. Cytokinetics is growing omecamtiv mecarbil, a cardiac muscle activator in sufferers with coronary heart failure. Cytokinetics can be growing aficamten, a next-in-class cardiac myosin inhibitor, at the moment the topic of SEQUOIA-HCM, the Section 3 scientific trial of aficamten in sufferers with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten can be being evaluated in non-obstructive HCM in Cohort 4 of the Section 2 scientific trial, REDWOOD-HCM. Cytokinetics can be growing reldesemtiv, an investigational quick skeletal muscle troponin activator, at the moment the topic of COURAGE-ALS, a Section 3 scientific trial in sufferers with amyotrophic lateral sclerosis (ALS). In 2023, Cytokinetics is celebrating its 25-year historical past of pioneering innovation in muscle biology and associated pharmacology targeted to illnesses of muscle dysfunction and situations of muscle weak spot.

For extra details about Cytokinetics, go to www.cytokinetics.com and comply with us on Twitter, LinkedIn, Fb and YouTube.

Ahead-Wanting Statements

This press launch and our Company Accountability Report include forward-looking statements for functions of the Personal Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to replace these forward-looking statements and claims the safety of the Act’s Protected Harbor for forward-looking statements. Examples of such statements, specific or implied, referring to Cytokinetics’ skill to acquire regulatory approval for any of its drug candidates in any indication or its analysis and growth actions, Cytokinetics’ skill to make sure or enhance entry to remedy utilizing any of its drug candidates, or Cytokinetics’ skill to scale back its greenhouse fuel emissions. Such statements are primarily based on administration’s present expectations, however precise outcomes might differ materially as a result of varied dangers and uncertainties, together with, however not restricted to the dangers associated to Cytokinetics’ enterprise outlines in Cytokinetics’ filings with the Securities and Change Fee. Ahead-looking statements are usually not ensures of future efficiency, and Cytokinetics’ precise outcomes of operations, monetary situation and liquidity, and the event of the business through which it operates, might differ materially from the forward-looking statements contained on this press launch. Any forward-looking statements that Cytokinetics makes on this press launch converse solely as of the date of this press launch. Cytokinetics assumes no obligation to replace its forward-looking statements whether or not because of new info, future occasions or in any other case, after the date of this press launch.

CYTOKINETICS® and the CYTOKINETICS and C-shaped emblem are registered logos of Cytokinetics within the U.S. and sure different international locations.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Company Communications, Investor Relations
(415) 290-7757

Leave a Comment

Your email address will not be published. Required fields are marked *